A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Locations
East Brunswick
Freehold
Howell
Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
Cancer Diagnosis
To Learn More Call
201-510-0910